Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Urinary Bladder Neoplasms 9Carcinoma, Transitional Cell 4Neoplasms 3Neoplasm Metastasis 3Breast Neoplasms 3Ureteral Neoplasms 2Urothelial Cancer 1Urologic Neoplasms 1Urogenital Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Renal Insufficiency 1Recurrence 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Locally Advanced or Metastatic Unresectable Urothelial Cancer 1Kidney Neoplasms 1

Interventions

Dexamethasone 64Cyclophosphamide 35pomalidomide 34Lenalidomide 34Rituximab 31Bortezomib 30venetoclax 28fludarabine 27Gemcitabine 21carfilzomib 20Paclitaxel 19pembrolizumab 17daratumumab 17Cisplatin 16Carboplatin 15Calcium Dobesilate 14Azacitidine 14ibrutinib 12Docetaxel 12Cytarabine 12obinutuzumab 11Nivolumab 11durvalumab 10Injections 10Doxorubicin 10Bevacizumab 10selinexor 9cemiplimab 9blinatumomab 9Cetuximab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Recurrence × vinflunine × Clear all
NCT02347332 2019-03-05

Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck Cancer

Pierre Fabre Medicament

Phase 3 Completed
459 enrolled 13 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡